CTRI/2022/09/045632尚未招募2 期
To determine the clinical efficacy, safety and molecular mechanisms of Guduchyadi tablets in combating COVID-19
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subject aged 20 to 60 years (both inclusive) of both gender
- •Subject with SARS-CoV-2 infection confirmed through reverse transcription followed by polymerase chain reaction (RT- PCR)
- •Subject with mild manifestations of COVID-19 (WHO ordinal score 1 or 2)
- •Subject with oxygen saturation ââ?°Â¥ 95% as measured by pulse oximetry
- •Subject with initial onset of signs/symptoms attributable to COVID-19 for ââ?°Â¤5 days prior to the day of randomization
- •Subject with ability to swallow and retain oral medication
- •Subject with willingness and ability to comply with trial and follow-up procedures
- •Subject with ability to understand the nature of this trial and give written informed consent
排除标准
- •Subject with RT-PCR positive COVID-19 with no symptoms
- •Subject currently hospitalized or expected to need hospitalization for COVID-19 within 48 hours of randomization
- •Subject in which the present episode of infection is a recurrence or reinfection of COVID-19 (within 90 days)
- •Subject having stage 2 hypertension (systolic blood pressure level > 160 mmHg and diastolic blood pressure of > 100 mmHg)
- •Subject using more than 3 anti-hypertensive drugs
- •Subject hospitalized for decompensated congestive heart failure in the last 12 months
- •Subject having HbA1c > 9.0%
- •Subject having Class 3 obesity (BMI ââ?°Â¥ 40)
- •Subject with aspartate aminotransferase (AST)/alanine transaminase (ALT) more than 3 times the upper limit of normal reference range
- •Subject who is pregnant, lactating or planning pregnancy during the study period
- •Subject of childbearing potential, unwilling to use highly effective contraception during their participation in the trial and for 2 weeks after study completion
- •Subject with a history of receiving any allopathic or alternative (herbal) medication, any antiviral drugs with reported activity against COVID-19 (ivermectin, favipiravir, hydroxychloroquine, lopinavir, and remdesivir) or warfarin therapy for the present COVID-19 episode within 7 days before enrolment
- •Subject on steroid or other immunosuppressive medication or having treatment within the last 3 months
- •Subject with unstable or life-threatening systemic diseases like immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, carcinoma, respiratory failure and end stage renal disease
- •Subject with a platelet count <100,000/Ã?¼L or who have received a platelet transfusion in the 5 days prior to randomization.
- •Subject having hypersensitivity or other contraindication to any of the components of the study interventions as determined by the principal investigator.
- •Subject with conditions that could limit gastrointestinal absorption of tablet contents.
- •Subject who is already participating in another trial or have received an experimental drug or have used an experimental medical device within 30 days prior to the planned start of procedure
- •Subject unlikely to comply with the procedure or complete the scheduled follow up visit, in the opinion of principal investigator
- •Employee of the principal investigator or study center with direct involvement in the proposed study or other studies under the direction of that principal investigator or study center
- •Other indication-based exclusion, in opinion of principal investigator
研究者
相似试验
进行中（未招募）
1 期
Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)on resectable Hepatocellular carcinoma (HCC)MedDRA version: 21.0Level: LLTClassification code: 10019828Term: Hepatocellular carcinoma non-resectable Class: 10029104CTIS2024-511538-11-00Institut Gustave Roussy40
已完成
不适用
Clinical Research to examine the efficacy and safety of Certolizmab pegolrheumatoid arthritisJPRN-UMIN000010664The Fukuoka RA Biologics Registry100
进行中（未招募）
不适用
Clinical Evaluation of the AqueSys Implant for the Treatment of ocular hypertension and open angle glaucomaOcular hypertension and open angle glaucomaEye - Diseases / disorders of the eyeACTRN12610000021077Aquesys Inc20
招募中
2 期
Clinical evaluation of the safety and effectiveness Oral capsules in the prevention and treatment of hair lossIRCT20190210042676N18Knowledge-based company of Janus20
招募中
2 期
Clinical evaluation of the safety and effectiveness of the nanofiber undereye pad to improve surface wrinkles and dark circles under the eyesIRCT20210130050179N9ano tarpak company10